C
Charles Peters
Researcher at University of Minnesota
Publications - 51
Citations - 4938
Charles Peters is an academic researcher from University of Minnesota. The author has contributed to research in topics: Transplantation & Hurler syndrome. The author has an hindex of 28, co-authored 51 publications receiving 4771 citations. Previous affiliations of Charles Peters include Peking Union Medical College & Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival.
John E. Wagner,Juliet N. Barker,Todd E. DeFor,K. Scott Baker,Bruce R. Blazar,Cindy R. Eide,Anne I. Goldman,John H. Kersey,William Krivit,Margaret L. MacMillan,Paul J. Orchard,Charles Peters,Daniel J. Weisdorf,Norma K.C. Ramsay,Stella M. Davies +14 more
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.
Journal ArticleDOI
Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children
Charles Peters,Elsa Shapiro,James A. Anderson,P. Jean Henslee-Downey,Martin R. Klemperer,Morton J. Cowan,E. Fred Saunders,Pedro A. deAlarcon,Clare J. Twist,James B. Nachman,Gregory A. Hale,Richard E. Harris,Marta K. Rozans,Joanne Kurtzberg,Guy H. Grayson,Thomas E. Williams,Carl Lenarsky,John E. Wagner,William Krivit +18 more
TL;DR: It is concluded that MPSIH patients, particularly those less than 24 months of age with a baseline MDI greater than 70, can achieve a favorable long-term outcome with continuing cognitive development and prolonged survival after successful BMT from a related donor with homozygous normal enzyme activity.
Journal ArticleDOI
Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome.
Charles Peters,Michael Balthazor,Elsa Shapiro,Roberta King,Craig Kollman,Janet D. Hegland,Jean Henslee-Downey,Michael E. Trigg,Morton J. Cowan,Jean E. Sanders,Nancy Bunin,Howard J. Weinstein,Carl Lenarsky,Peter Falk,Richard R. Harris,Tom Bowen,Thomas E. Williams,Guy H. Grayson,Phyllis Warkentin,Leonard Sender,Valerie A. Cool,Mary R. Crittenden,Seymour Packman,Paige Kaplan,Lawrence A. Lockman,James Anderson,William Krivit,Kathryn Dusenbery,John Wagner +28 more
TL;DR: It is concluded that MPS I H patients with a baseline MDI greater than 70 who are engrafted survivors following URD BMT can achieve a favorable long-term outcome and improved cognitive function.
Journal ArticleDOI
Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.
Charles Peters,Lawrence R. Charnas,Ye Tan,Richard S. Ziegler,Elsa Shapiro,Todd E. DeFor,Satkiran S. Grewal,Paul J. Orchard,S Abel,Anne I. Goldman,Norma K.C. Ramsay,Kathryn E. Dusenbery,Daniel J. Loes,Lawrence A. Lockman,Shunichi Kato,Patrick R. Aubourg,Hugo W. Moser,William Krivit +17 more
TL;DR: It is concluded that boys with early-stage disease benefit from HCT, whereas boys with advanced disease may be candidates for experimental therapies.
Journal ArticleDOI
Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines.
Charles Peters,Colin G. Steward +1 more
TL;DR: The primary goals of HCT for selected inherited metabolic diseases have been to promote long-term survival with donor-derived engraftment and to optimize the quality of life.